Probucol.
The purpose of this review article is twofold. It seeks to present an overview of research studies conducted on the many effects of probucol, and it demonstrates the interest in pursuing studies on probucol"s multiple specific actions and its future as a therapeutic agent. Within this article, the results of animal studies, experimental human studies, and clinical human studies are detailed, as is information on toxicology studies and on the side effects of the drug.
Pfuetze
K D
KD
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 10550 Quivira Road, Suite 220, Overland Park, KS 66215, USA.
Dujovne
C A
CA
D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001057:Apolipoproteins E / Q000096:biosynthesis* / Q000187:drug effects; D001161:Arteriosclerosis / Q000503:physiopathology / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002340:Carotid Artery Diseases / Q000503:physiopathology / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007333:Insulin Resistance; D009203:Myocardial Infarction / Q000150:complications / Q000473:pathology; D011341:Probucol / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D014655:Vascular Resistance
D000924:Anticholesteremic Agents; D000975:Antioxidants; D001057:Apolipoproteins E; D011341:Probucol